Ligands for imaging cardiac innervation
    2.
    发明授权
    Ligands for imaging cardiac innervation 有权
    用于成像心脏神经支配的配体

    公开(公告)号:US08491868B2

    公开(公告)日:2013-07-23

    申请号:US12448575

    申请日:2007-12-21

    摘要: Novel compounds that find use as imaging agents within nuclear medicine applications (PET imaging) for imaging of cardiac innervation are disclosed. These PET based radiotracers may exhibit increased stability, decreased NE release (thereby reducing side effects), improved quantitative data, and/or high affinity for VMAT over prior radiotracers. Methods of using the compounds to image cardiac innervation are also provided. In some instances the compounds are developed by derivatizing certain compounds with 18F in a variety of positions: aryl, alkyl, a keto, benzylic, beta-alkylethers, gamma-propylalkylethers and beta-proplylalkylethers. Alternatively or additionally, a methyl group a is added to the amine, and/or the catechol functionality is either eliminated or masked as a way of making these compounds more stable.

    摘要翻译: 公开了用于心脏神经支配成像的核医学应用(PET成像)中用作成像剂的新型化合物。 这些基于PET的放射性示踪剂可能表现出增加的稳定性,减少NE释放(从而减少副作用),改进的定量数据,和/或对先前的放射性示踪剂对VMAT的高亲和力。 还提供了使用化合物成像心脏神经支配的方法。 在某些情况下,化合物通过在各种位置上衍生化某些化合物而形成:芳基,烷基,酮基,苄基,β-烷基醚,γ-丙基烷基醚和β-丙基烷基醚。 或者或另外,将甲基a加入到胺中,和/或儿茶酚官能团被消除或掩蔽,作为使这些化合物更稳定的方式。

    Vitronectin receptor antagonist pharmaceuticals

    公开(公告)号:US06683163B2

    公开(公告)日:2004-01-27

    申请号:US09948807

    申请日:2001-09-07

    IPC分类号: C07F500

    摘要: The present invention describes novel compounds of the formula: (Q)d-Ln-Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

    Vitronectin receptor antagonist pharmaceuticals
    8.
    发明授权
    Vitronectin receptor antagonist pharmaceuticals 失效
    Vitronectin受体拮抗剂药物

    公开(公告)号:US06511649B1

    公开(公告)日:2003-01-28

    申请号:US09599364

    申请日:2000-06-21

    IPC分类号: A61K5100

    摘要: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

    摘要翻译: 本发明描述了新的下式化合物:可用于癌症的诊断和治疗,对患者肿瘤成像的方法,以及治疗患者癌症的方法。 本发明还提供了可用于监测治疗性血管生成治疗和破坏新的血管生成脉管系统的新型化合物。 本发明还提供可用于成像动脉粥样硬化,再狭窄,心脏缺血和心肌再灌注损伤的新型化合物。 本发明还提供了可用于治疗类风湿性关节炎的新化合物。 药物由与血管发生期间上调的受体结合的靶向部分,任选的连接基团和治疗有效的放射性同位素或诊断上有效的可成像部分组成。 可成像部分是伽马射线或正电子发射放射性同位素,磁共振成像造影剂,X射线造影剂或超声造影剂。

    Vitronectin receptor antagonist pharmaceuticals

    公开(公告)号:US06511648B2

    公开(公告)日:2003-01-28

    申请号:US09465300

    申请日:1999-12-17

    IPC分类号: A61K5100

    摘要: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention further provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention still further provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

    Vitronectin receptor antagonist pharmaceuticals
    10.
    发明授权
    Vitronectin receptor antagonist pharmaceuticals 失效
    Vitronectin受体拮抗剂药物

    公开(公告)号:US07332149B1

    公开(公告)日:2008-02-19

    申请号:US09599890

    申请日:2000-06-21

    摘要: The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. The present invention also provides novel compounds useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature. The present invention also provides novel compounds useful for imaging atherosclerosis, restenosis, cardiac ischemia, and myocardial reperfusion injury. The present invention also provides novel compounds useful for the treatment of rheumatoid arthritis. The pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety. The imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.

    摘要翻译: 本发明描述了新的下式化合物:<?in-line-formula description =“In-line Formulas”end =“lead”?>(Q) 对于癌症的诊断和治疗有用的<?in-line-formula description =“在线公式”end =“tail”?>,肿瘤成像方法 患者,以及在患者中治疗癌症的方法。 本发明还提供了可用于监测治疗性血管生成治疗和破坏新的血管生成脉管系统的新型化合物。 本发明还提供了用于成像动脉粥样硬化,再狭窄,心脏缺血和心肌再灌注损伤的新型化合物。 本发明还提供了可用于治疗类风湿性关节炎的新化合物。 药物由与血管发生期间上调的受体结合的靶向部分,任选的连接基团和治疗有效的放射性同位素或诊断上有效的可成像部分组成。 可成像部分是伽马射线或正电子发射放射性同位素,磁共振成像造影剂,X射线造影剂或超声造影剂。